Betty Chang
Corporate Officer/Principal at SUMMIT THERAPEUTICS INC.
Profile
Dr. Betty Chang is a Head-Research, Oncology & Inflammation at Summit Therapeutics, Inc. Dr. Chang was previously employed as a Chief Operating Officer & EVP-Product Development by Angarus Therapeutics, Inc., an Associate Director by Alder Biopharmaceuticals, Inc., a Vice President-Research & Biology by Pharmacyclics LLC, an Associate Director by Rigel Pharmaceuticals, Inc., and a Senior Vice President-Translational Research by Molecular Templates, Inc. She received her doctorate degree from the University of California, Davis.
Betty Chang active positions
| Companies | Position | Start |
|---|---|---|
| SUMMIT THERAPEUTICS INC. | Corporate Officer/Principal | 2021-05-31 |
Former positions of Betty Chang
| Companies | Position | End |
|---|---|---|
Angarus Therapeutics, Inc.
 Angarus Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Angarus Therapeutics, Inc. engages in the development of immuno-oncology therapies. It specializes in modulating the tumor microenvironment by activating innate immunity. The company was founded by Ling Yin Li, Chih Ping Liu, and Mark Smith and is headquartered in Sunnyvale, CA. | Chief Operating Officer | 2018-12-31 |
| PHARMACYCLICS, INC. | Chief Tech/Sci/R&D Officer | 2017-12-31 |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 2009-10-31 |
| RIGEL PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2008-12-31 |
| MOLECULAR TEMPLATES, INC. | Corporate Officer/Principal | - |
Training of Betty Chang
| University of California, Davis | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| SUMMIT THERAPEUTICS INC. | Health Technology |
| MOLECULAR TEMPLATES, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Angarus Therapeutics, Inc.
Angarus Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Angarus Therapeutics, Inc. engages in the development of immuno-oncology therapies. It specializes in modulating the tumor microenvironment by activating innate immunity. The company was founded by Ling Yin Li, Chih Ping Liu, and Mark Smith and is headquartered in Sunnyvale, CA. | Health Services |
- Stock Market
- Insiders
- Betty Chang
